| 摘要 |
The invention provides a method of preventing, delaying, or reversing the progression of Alzheimer's disease by administering an Abeta<SUB>42 </SUB>lowering agent to a mammal under conditions in which levels of Abeta<SUB>42 </SUB>are selectively reduced, levels of Abeta<SUB>38 </SUB>are increased, and levels of Abeta<SUB>40 </SUB>are unchanged. The invention provides methods and materials for developing and identifying Abeta<SUB>42 </SUB>lowering agents. In addition, the invention provides methods for identifying agents that increase the risk of developing, or hasten progression of, Alzheimer's disease. The invention also provides compositions of Abeta<SUB>42 </SUB>lowering agents and antioxidants, Abeta<SUB>42 </SUB>lowering agents and non-selective secretase inhibitors, as well as Abeta<SUB>42 </SUB>lowering agents and acetylcholinesterase inhibitors. The invention also provides kits containing Abeta<SUB>42 </SUB>lowering agents, antioxidants, non-selective secretase inhibitors, and/or acetylcholinesterase inhibitors as well as instructions related to dose regimens for Abeta<SUB>42 </SUB>lowering agents, antioxidants, non-selective secretase inhibitors, and acetylcholinesterase inhibitors.
|
